The UK and US have reached a landmark trade agreement that will preserve zero duties on UK drug exports being sold in the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has committed to raise expenditure on pharmaceuticals through the public health system. This commitment ensures that import taxes on these key products will stay at nothing for a timeframe of the next three years.
This development comes after previous warnings to hike duties on patented pharmaceutical imports, with figures discussed up to 100%.
"This agreement between the UK bolsters the global environment for new treatments and introduces long-overdue equity to transatlantic medicine commerce," a statement noted.
Economic Significance
Drugs are one of the UK's most significant exports to the America, which is clearly the biggest buyer for leading British pharmaceutical firms.
Export figures reveal that in the one-year period to the end of September, the UK shipped medicines totaling over eleven billion pounds to the US. This amount accounted for 17.4% of British export trade in that period.
"This guarantee safeguards jobs, increases capital expenditure and sets the stage for the UK to become a international leader for medical research," a government official stated.
Detailed NHS Changes
The pact involves several notable commitments from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it judges new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a target to raise total public funding on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to prevent overspending will be capped at fifteen percent. Previously, rebates topped 20%.
Broader Context
The deal follows a protracted tension between the sector and the ministers over medicine costs and approval rates.
The disagreement were intensified by arguments that US customers were paying significantly more for the same drugs than patients in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been paused or scrapped, while substantial investments have been announced toward American operations.
A senior figure stated that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had declined as a share of its overall budget over the last ten years.
